GLOSTRUP, DENMARK--(Marketwired - August 30, 2013) - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, and Omnyx, LLC (a joint venture
Healthcare and the University of Pittsburgh Medical Center) a leader in
pathology, announced today that they are launching clinical image analysis
digital pathology in Europe.
By providing quantitative results for HercepTest, Dako and Omnyx enable a
confident diagnosis, with an overall aim of supporting pathologists in
generating accurate, objective and reproducible diagnostic results.
As part of the collaboration which began in 2010, Dako has used its
staining and image analysis to develop algorithms that are incorporated
Omnyx digital pathology platform as part of Omnyx's overall strategy of
providing pathologists with a comprehensive digital workflow. The
image analysis tool is now accessible in the Omnyx system and has been
specifically customized for Dako's breast cancer prognostic markers.
"Omnyx envisions a future where image analysis and workflow empower
to make confident clinical decisions ultimately leading to better patient
said Jim LaFrance, CEO of Omnyx. "Our partnership with Dako allows us to
image analysis to clinicians who use Dako tests. Image analysis for
markers within the Omnyx Integrated Digital Pathology workflow provides
pathologists with a powerful set of tools to improve both accuracy and
Digital pathology converts glass slides into digital images and efficiently
manages the resulting image data. It enables pathologists to improve
productivity by providing a virtual means of reviewing tissue sections
handling traditional glass slides, and it offers digital image analysis
help pathologists interpret tissue-based test results objectively. Digital
pathology holds tremendous potential for standardizing test interpretation
enabling greater accuracy in cancer diagnostics.
"With this offering, Dako and Omnyx support pathologists in making
efficient diagnoses based on both subjective and quantitative measures,"
Jakob Mohr Christensen, vice president of Global Marketing at Dako.
"Additionally, the algorithms link digital scanners to Dako reagents and
staining instruments, which give customers a complete and integrated
Dako is committed to continually improving patient care by finding ways to
further enhance the standards and accuracy in cancer diagnostics."
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
Omnyx, LLC is a joint venture of GE Healthcare and the University of
Medical Center with locations in Pittsbugh, Pa., and Piscataway, N.J. The
company is developing an enterprise platform to transform the scope of
to an all-digital workflow. The company will sell their digital pathology
platform to clinical labs and offer an enterprise software platform for
management, workflow automation, image analysis algorithms and system
integration along with its high speed whole-slide scanners. Close
with pathologists at UPMC and other institutions along with their
with GE Healthcare allows Omnyx to focus its innovation on the needs of
pathologists worldwide. Omnyx digital pathology products are currently in
development and have not yet been cleared by the U.S. Food and Drug
Administration. Information about Omnyx is available at www.omnyx.com.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's reagents,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees,
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE